biota - the next csl

The FACTS
Source of Information: http://www.theaustralian.news.com.au/story/0,25197,25823366-12377,00.html

Quote: “This brought royalties for the 2008/09 year to $45 million on sales of $638.7 million, up from $20.5 million on sales of $304.4 million in 2007/08.

And Source of information:
http://www.roche.com/med-cor-2009-07-23-e.pdf

Quote: ”Global sales of the antiinfluenza medicine Tamiflu (oseltamivir) rose 203% to 1.0 billion Swiss francs in the first half-year, following the rapid worldwide spread of a new strain of influenza A/H1N1 (‘swine flu’)” and
“Responding to the current pandemic threat level, Roche and its network of manufacturing partners have scaled up Tamiflu production and by the start of 2010 will be able to supply up to 400 million packs annually, should the need arise. In addition, Roche some time ago granted sublicences to three manufacturers to produce generic oseltamivir for pandemic use in China, India and specified developing countries:”

BTA shareholders, there is no doubt what-so-ever that a $10 share price mentioned by other posters should be easily achievable for Biota.

However IF Relenza is marketed to achieve its true potentials and the company is managed competently, a share price well beyond $10 could be achieved when one considers the huge potentials for LANI.

Despite all the problems afflicting Tamiflu (H1N1 resistance & the psychotic effects on young patients), Roche sold CHF1billion (approx 1.14 billion Australian dollars) in the first half of this year compared to GSK sold $304.4 million of Relenza and presold 190 million doses of yet-to-be-available Pandemic Flu Vaccine.
And Peter Cook the idiotic CEO is singing praises how well he (Peter Cook) and GSK is selling Relenza.

Yes Sir, 190 million courses of Relenza per annum is FANTASTIC NEWS and the share price deserves to be many times times higher than Friday closing $1.88 sp.

However Relenza is a superior product to Tamiflu. Peter Cook should be on the phone to GSK demanding answers.
- $1.14 billion of the inferior Tamilu is sold for the first half year compared to $204.4 million of the superior Relenza for the full year and
- Roche is gearing up production capacity to 400 million packs compared to GSK’s 190 million courses.

Don’t these facts tell a story about your CEO?
Peter Cook has to be a complete idiot to be praising GSK. In 2006/07 Gilead sued Roche and settled the lawsuit with an increased 20% royalty and increased production capacity and went on to make billions from the Avian-flu outbreak.

BTA has the products to be as great as CSL. Get rid of the parasites so that Biota will achieve its full glory.

For more information, read these posts:
http://www.hotcopper.com.au/post_single.asp?fid=1&tid=936783&msgid=5217474

http://www.hotcopper.com.au/post_single.asp?fid=1&tid=944688&msgid=5264338

http://www.hotcopper.com.au/post_single.asp?fid=1&tid=944330&msgid=5263917